Advertisement
Advertisement
At close: 04:00PM EDT
After hours:
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 30.53 |
| Open | 30.86 |
| Bid | 28.50 x 1000 |
| Ask | 31.13 x 800 |
| Day's Range | 29.96 - 31.12 |
| 52 Week Range | 6.03 - 35.26 |
| Volume | |
| Avg. Volume | 421,479 |
| Market Cap | 1.458B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37.33 |
- Zacks
Arcellx, Inc. (ACLX) Reports Q4 Loss, Misses Revenue Estimates
Arcellx, Inc. (ACLX) delivered earnings and revenue surprises of -7.04% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Arcellx Provides Fourth Quarter and Year-End 2022 Financial Results and Business Highlights
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2022.
- Zacks
Is a Surprise Coming for Arcellx (ACLX) This Earnings Season?
Arcellx (ACLX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2023 Yahoo. All rights reserved.
